Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Katherine Reigstad

Vascular Surgery Willmar, MN Medical Doctor

NPI 1386872539 CMS profile 1383983

101 Willmar Ave Sw, Acmc-Willmar, Willmar, MN 56201

Open in the dashboard

General payments

$6,539

74 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Katherine Reigstad of Willmar, MN is reported in the CMS Open Payments database as having received $6,539 across 74 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 57th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $944 11
2024 General $3,207 36
2023 General $333 7
2022 General $1,307 13
2021 General $34 1
2020 General $704 5
2019 General $9 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Katherine Reigstad
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Katherine Reigstad were reported at $944. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Katherine Reigstad Vascular Surgery median Middle half National median
2019 $9 $796 $226–$2,363 $163
2020 $704 $348 $118–$1,110 $114
2021 $34 $471 $158–$1,421 $132
2022 $1,307 $725 $222–$2,183 $149
2023 $333 $836 $257–$2,440 $160
2024 $3,207 $909 $252–$2,619 $164
2025 $944 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. MIMEDX Group, Inc. $1,492 6 payments
  2. Bard Peripheral Vascular, Inc. $1,403 18 payments
  3. Medtronic, Inc. $1,206 19 payments
  4. Stryker Corporation $752 6 payments
  5. Cook Incorporated $647 3 payments
  6. Shockwave Medical, Inc $292 5 payments
  7. Surmodics, Inc. $264 4 payments
  8. Penumbra, Inc. $87 1 payment
  9. Silk Road Medical, Inc. $86 2 payments
  10. Organogenesis Inc. $65 3 payments
  11. Other $246 7 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $3,796 17 payments
  2. Food and Beverage $2,743 57 payments
Products named General payments · program years 2019–2025
  1. FLOWTRIEVER CATHETER, S $734 5 payments
  2. CT THROMBECTOMY SYSTEM KIT $734 5 payments
  3. Cook Medical Zenith $647 3 payments
  4. TurboHawk $610 11 payments
  5. VENASEAL $525 6 payments
  6. Pounce Thrombectomy $264 4 payments
  7. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter $263 4 payments
  8. Sublime 014 Rx PTA Balloon Dilatation Catheter $147 1 payment
  9. Sublime Radial Access 018 RX PTA Dilatation Catheter $147 1 payment
  10. Sublime Radial Access Guide Sheath $147 1 payment
  11. Other $1,446 40 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

191

Median for Vascular Surgery: 122

Drug cost

$2,754

Median for Vascular Surgery: $14,135

Branded share of claims

36.1%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Cilostazol Generic 73 $1,642
Clopidogrel Clopidogrel Bisulfate Brand 69 $837
Pantoprazole Sodium Generic 15 $183
Oxycodone Hcl Generic 34 $91

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 144 billing codes

Paid by Medicare

$127,184

Of which drugs: $12,962

Medicare patients

239

Average age 75

Services billed

2,463

120 women, 119 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 50%
Ischemic heart disease 49%
Diabetes 42%
Arthritis 41%
Heart failure 36%
Depression 33%
Atrial fibrillation 31%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 12 1,302 $133

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

74 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record